Pharmaceutical Analysis & Statistics in Europe Countries, November 2014

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Publishers

You might be interested in: Therapeutics, Drug, Cancer, more »

1-50 of about 12 000 reports

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: HER2-Positive Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023

  • $ 6 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: HER2-Positive Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in ...

  • Industries : Pathology
  • Countries : Germany, Spain, Italy, France, United Kingdom, World, Europe
PharmaPoint: Asthma - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: Asthma - 5EU Drug Forecast and Market Analysis to 2023

  • $ 6 995
  • Industry report
  • August 2014
  • by Global Data

PharmaPoint: Asthma - 5EU Drug Forecast and Market Analysis to 2023 Summary Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through ...

  • Industries : Drug and Medication
  • Countries : Spain, France, Italy, Germany, United Kingdom, Europe, World
MarketVIEW: Herpes Zoster (adult) vaccines

MarketVIEW: Herpes Zoster (adult) vaccines

  • $ 4 995
  • Industry report
  • October 2014
  • by VacZine Analytics Group Of Assay Advantage Ltd

Varicella-zoster virus is a ubiquitous human alphaherpesvirus, which after infection in childhood causes a relatively mild self-limiting illness. However, if the virus becomes reactivated later on in life ...

  • Industries : Drug and Medication
  • Countries : United Kingdom, Argentina, Brazil, Mexico, Canada, Spain, Italy, France, Germany, Europe, World, United States, South America, North America
Physiotherapy Equipment Market by Equipment (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise Ball), Applications (Pediatric, Musculoskeletal) & by End Users (Hospitals), Advanced technologies - Global Forecast to 2019

Physiotherapy Equipment Market by Equipment (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise Ball), Applications (Pediatric, Musculoskeletal) & by End Users (Hospitals), Advanced technologies - Global Forecast to 2019

  • $ 4 650
  • Industry report
  • September 2014
  • by MarketsandMarkets

Developing markets such as Middle East, Australia, New Zealand, China, India, and Malaysia are lucrative markets for physiotherapy equipment, owing to favorable government incentives and developing healthcare ...

  • Industries : Therapy
  • Countries : World, North America, Europe, Germany, Canada, United States, China, Australia
EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2023

EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • October 2014
  • by Global Data

EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2023 Summary Dyslipidemia is a condition in which one or more of the serum lipid levels are abnormal. It is a well-established risk factor for cardiovascula ...

  • Industries : Pathology
  • Countries : Germany, Japan, China, World, United States
EpiCast Report: Allergic Conjunctivitis - Epidemiology Forecast to 2023

EpiCast Report: Allergic Conjunctivitis - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • October 2014
  • by Global Data

EpiCast Report: Allergic Conjunctivitis - Epidemiology Forecast to 2023 Summary Allergic conjunctivitis is an inflammation of the eye resulting from an allergic reaction to allergy causing substances (external ...

  • Industries : Pathology
  • Countries : World, United States, Spain, Italy, France, Germany
EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023

EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • August 2014
  • by Global Data

EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023 Summary Renal cell carcinoma (RCC) is a type of kidney cancer that originates in the lining of the proximal convoluted tubule, a part ...

  • Industries : Pathology
  • Countries : Japan, China, World, United States, Spain, Italy, France, Germany
Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Herceptin (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : World, United States, Spain, Italy, France, Germany, Japan, China, United Kingdom, Europe
Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Perjeta (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : Japan, World, Spain, Italy, France, Germany, China, United States, United Kingdom, Europe
Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Kadcyla (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : Japan, World, Spain, Italy, France, Germany, China, United States, United Kingdom, Europe
Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Tykerb (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, China, Europe, United States, United Kingdom
Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Neratinib (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, China, World, United States, United Kingdom, Europe
Flovent (Asthma) - Forecast and Market Analysis to 2023

Flovent (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Flovent (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Flovent (Asthma) - Forecast and Market Analysis to 2023”. The asthma ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan
Pulmicort (Asthma) - Forecast and Market Analysis to 2023

Pulmicort (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Pulmicort (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Pulmicort (Asthma) - Forecast and Market Analysis to 2023”. The ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Advair (Asthma) - Forecast and Market Analysis to 2023

Advair (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Advair (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Advair (Asthma) - Forecast and Market Analysis to 2023”. The asthma ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Symbicort (Asthma) - Forecast and Market Analysis to 2023

Symbicort (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Symbicort (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Symbicort (Asthma) - Forecast and Market Analysis to 2023”. The ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023

Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023”. ...

  • Industries : Pathology
  • Countries : World, Australia, Spain, Italy, France, Germany, Japan, Europe, United States, United Kingdom
Flutiform (Asthma) - Forecast and Market Analysis to 2023

Flutiform (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Flutiform (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Flutiform (Asthma) - Forecast and Market Analysis to 2023”. The ...

  • Industries : Drug and Medication
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United Kingdom, Europe
Fostair (Asthma) - Forecast and Market Analysis to 2023

Fostair (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Fostair (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Fostair (Asthma) - Forecast and Market Analysis to 2023”. The asthma ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, World, United Kingdom, Europe
Singulair (Asthma) - Forecast and Market Analysis to 2023

Singulair (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Singulair (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Singulair (Asthma) - Forecast and Market Analysis to 2023”. The ...

  • Industries : Drug and Medication
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Xolair (Asthma) - Forecast and Market Analysis to 2023

Xolair (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Xolair (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Xolair (Asthma) - Forecast and Market Analysis to 2023”. The asthma ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Spiriva (Asthma) - Forecast and Market Analysis to 2023

Spiriva (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Spiriva (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Spiriva (Asthma) - Forecast and Market Analysis to 2023”. The asthma ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Fluticasone Furoate (Asthma) - Forecast and Market Analysis to 2023

Fluticasone Furoate (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Fluticasone Furoate (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Fluticasone Furoate (Asthma) - Forecast and Market Analysis ...

  • Industries : Pathology
  • Countries : Japan, Australia, World, Spain, Italy, France, Germany, United States, United Kingdom, Europe
Cinquil (Reslizumab) (Asthma) - Forecast and Market Analysis to 2023

Cinquil (Reslizumab) (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Cinquil (Reslizumab) (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Cinquil (Reslizumab) (Asthma) - Forecast and Market Analysis ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Bosatria (Mepolizumab) (Asthma) - Forecast and Market Analysis to 2023

Bosatria (Mepolizumab) (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Bosatria (Mepolizumab) (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Bosatria (Mepolizumab) (Asthma) - Forecast and Market ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Lebrikizumab (Asthma) - Forecast and Market Analysis to 2023

Lebrikizumab (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Lebrikizumab (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Lebrikizumab (Asthma) - Forecast and Market Analysis to 2023”. ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Benralizumab (Asthma) - Forecast and Market Analysis to 2023

Benralizumab (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Benralizumab (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Benralizumab (Asthma) - Forecast and Market Analysis to 2023”. ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Dupilumab (Asthma) - Forecast and Market Analysis to 2023

Dupilumab (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Dupilumab (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Dupilumab (Asthma) - Forecast and Market Analysis to 2023”. The ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Quilizumab (Asthma) - Forecast and Market Analysis to 2023

Quilizumab (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Quilizumab (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Quilizumab (Asthma) - Forecast and Market Analysis to 2023”. ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Tralokinumab (Asthma) - Forecast and Market Analysis to 2023

Tralokinumab (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Tralokinumab (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Tralokinumab (Asthma) - Forecast and Market Analysis to 2023”. ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
About 7 700 reports

Download Unlimited Documents from Trusted Public Sources

Pathology Description in the UK - Forecast

  • Governing Body
  • November 2014
    6 pages
  • Hiv  

    Aids  

  • United Kingdom  

    World  

View report >

33 Companies

Read our Company Profiles

GlaxoSmithKline P.L.C.

United States

GlaxoSmithKline PLC

United Kingdom

Johnson and Johnson

United States

Novartis Inc.

Switzerland

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.